-

Abcuro Announces Participation in Upcoming Investor Conferences

NEWTON, Mass.--(BUSINESS WIRE)--Abcuro, Inc., a clinical stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T cells, today announced that Alex Martin, Chief Executive Officer, will present at the following investor conferences.

  • Morgan Stanley 22nd Annual Global Healthcare Conference: Presentation on September 5, 2024, at 2:35 pm E.T.
  • Stifel Virtual Immunology and Inflammation Summit: Presentation on September 18, 2024, at 2:00 pm E.T.

About Abcuro

Abcuro is a clinical stage biotechnology company developing first-in-class immunotherapies for the treatment of autoimmune diseases and cancer through precise modulation of highly cytotoxic T cells. The company’s lead program is ulviprubart (ABC008) and is currently in clinical trials for inclusion body myositis (IBM) and T cell large granular lymphocytic leukemia.

For more information, visit us on LinkedIn and at abcuro.com.

Contacts

Matthew DeYoung
Investor Relations and Media
Argot Partners
abcuro@argotpartners.com

Industry:

Abcuro, Inc.

Release Versions
English

Contacts

Matthew DeYoung
Investor Relations and Media
Argot Partners
abcuro@argotpartners.com

More News From Abcuro, Inc.

Abcuro to Present Interim Phase 1 Data Evaluating Ulviprubart in Patients with T Cell Large Granular Lymphocytic Leukemia at the 67th American Society of Hematology Annual Meeting

NEWTON, Mass.--(BUSINESS WIRE)--Abcuro, Inc., a late-stage clinical biotechnology company developing potential first-in-class immunotherapies for the benefit of people living with debilitating and progressive rare autoimmune diseases and cancers, today announced that the Company will present interim data from the Phase 1/2 clinical trial evaluating the safety, tolerability, and hematological effect of ulviprubart in patients with T cell large granular lymphocytic leukemia (T-LGLL) who suffer fr...

Abcuro Appoints George Eldridge as Chief Financial Officer

NEWTON, Mass.--(BUSINESS WIRE)--Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T cells, today announced the appointment of George Eldridge as Chief Financial Officer (CFO). Mr. Eldridge brings more than 30 years of executive leadership experience in finance and business operations across the biotechnology industry. “George brings industry-leading financial expertise that will b...

Abcuro Appoints Courtney Cupples as Chief Commercial Officer

NEWTON, Mass.--(BUSINESS WIRE)--Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T cells, today announced the appointment of Courtney Cupples as Chief Commercial Officer (CCO). Ms. Cupples brings more than 25 years of global commercial leadership and rare disease product launch experience. “We are excited to welcome Courtney to Abcuro as a key member of the leadership team as we...
Back to Newsroom